Abstracts tagged "IL-6R signaling"

Abstract Number: 6 • 2019 ACR/ARP Annual Meeting
A Novel Role for Extracellular Sulfatase-2 in Mediating IL-6-induced Adhesion and Migration Molecules in Human Rheumatoid Arthritis Synovial Fibroblasts
Ruby Siegel¹ and Salahuddin Ahmed ², ¹Washington State University Spokane, Spokane, WA, ²Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA. Division of Rheumatology, University of Washington School of Medicine, Seattle, WA, Spokane, WA
Background/Purpose: Interleukin-6 (IL-6) promotes synovial hyperplasia by inducing mediators of adhesion, migration and leukocyte infiltration in rheumatoid arthritis (RA). The extracellular enzymes sulfatase-2 (Sulf-2) and…
Abstract Number: 1398 • 2019 ACR/ARP Annual Meeting
Sarilumab and Tocilizumab Receptor Occupancy (RO), and Effects on C-Reactive Protein (CRP) Levels, in Patients with Rheumatoid Arthritis (RA)
Christine Xu¹, Patrick Nolain ², Qiang Lu ³, Anne Paccaly ⁴, Melitza Iglesias-Rodriguez ⁵, Gregory St John ⁶, Chad Nivens ⁴, Rafael Maldonado ⁷, Tomonori Ishii ⁸, Ernest Choy ⁹ and Vanaja Kanamaluru ³, ¹Sanofi, Bridgewater, NJ, ²Sanofi-Aventis, Montpellier, France, ³Sanofi, Bridgewater, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, ⁵Sanofi Genzyme, Cambridge, MA, ⁶Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁷Pompeu Fabra University, Barcelona, Spain, ⁸Tohoku University Hospital, Sendai, Japan, ⁹Cardiff University School of Medicine, Cardiff, United Kingdom
Background/Purpose: The in vitro binding affinity of sarilumab (KD 61.9 pM) for the human interleukin-6 receptor (IL-6R) is 15–22-fold higher than that of tocilizumab. This…
Abstract Number: 930 • 2018 ACR/ARHP Annual Meeting
Joint Location-Specific IL6 and JAK-STAT Signaling in Rheumatoid Arthritis (RA) Fibroblast-like Synoviocytes (FLS)
Deepa Hammaker¹, Gyrid Nygaard¹, Amanda Kuhs¹, Rizi Ai², David L. Boyle¹, Wei Wang³ and Gary S. Firestein¹, ¹Medicine, University of California San Diego, La Jolla, CA, ²University of California San Diego, La Jolla, CA, ³Chemistry and Biochemistry, University of California San Diego, La Jolla, CA
Background/Purpose: Recent studies suggest that epigenetic marks distinguish FLS isolated from different joints in RA. Hip and knee joint-derived FLS, in particular, have distinctive DNA…
Abstract Number: 1825 • 2018 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Associated Haploinsufficiency in PTPN2 Enhances Severity of IL-17 Mediated Autoimmune Arthritis
Mattias N. D. Svensson¹, Karen M. Doody², Shen Yang³, Dennis J. Wu⁴, Cristiano Sacchetti⁵, Isabelle Aubry⁶, Piotr Mydel⁷, Mitchell Kronenberg⁸, Michel L. Tremblay⁹ and Nunzio Bottini², ¹Department of Medicine, University of California San Diego, La Jolla, CA, ²Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, ³Medicine, University of California San Diego, La Jolla, CA, ⁴University of California San Diego, San Diego, CA, ⁵Rheumatology, University of California San Diego, La Jolla, CA, ⁶Biochemistry, McGill University, Montreal, QC, Canada, ⁷University of Bergen, Bergen, Norway, ⁸Developmental Immunology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, ⁹Biochemistry, McGill University, Montréal, QC, Canada
Background/Purpose: Genetic polymorphisms at the PTPN2 locus, which encodes the tyrosine phosphatase TC-PTP, cause reduced gene expression and are linked to rheumatoid arthritis (RA). PTPN2…
Abstract Number: 972 • 2017 ACR/ARHP Annual Meeting
JAK/STAT Mediated Inhibition of Mir-23a~24-2~27a Cluster Potentiates Activation of CD14+ Monocytes in Treatment-Resistant RA
Marina Frleta-Gilchrist, Donna McIntyre, Aziza Elmesmari, Lynn Stewart, Derek Baxter, Mariola Kurowska-Stolarska, Derek Gilchrist and Iain B. McInnes, Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: While emerging and existing treatments of RA allow better options and clinical outcomes for patients, studies informing drug resistant states and further clinical therapeutic…
Abstract Number: 1568 • 2017 ACR/ARHP Annual Meeting
Existence of IL-6 and IL-17 Mediated Inflammation Amplifier Loop in Reactive Arthritis
Ramnath Misra¹, Sandeep Kumar², Rajeev Singh³, Abhisek Singh⁴, Daisuke Kamimura⁵, Smriti Chaurasia², Yasunobu Aria⁶, Tori Austria⁷, Ratnadeep Mukherjee⁸, Balachandran Ravindran⁹, Vikas Agarwal² and Masaaki Murakami¹⁰, ¹Clinical Immunology, Sanjay Gandhi Postgraduate of Medical Sciences, Lucknow, India, ²Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ³Biochemistry, King George Medical University, Lucknow, India, ⁴Division of Molecular Neroimmunology, Post Doctoral Fellow, Sapporo, Japan, ⁵Molecular Neuroimmunology, Lecturer, Sapporo 060-0815,, Japan, ⁶Division of Molecular Neuroimmunology, Assistant Professor, Sapporo 060-0815, Japan, ⁷Division of Molecular Neuroimmunology, Special appointed - Assistant Professor, Sapporo 060-0815, Japan, ⁸Institute of Life Sciences, Ph D student, Bhubaneswar, India, ⁹Institute of Life Sciences, Distinguished Scientist, Bhubaneswar, India, ¹⁰Institute of Genetic Medicine, Director, Sapporo 060-0815, Japan
Background/Purpose: F759 mice with a single amino-acid substitution in signal transducer subunit of IL-6 receptor gp130 (Y759F) develops arthritisspontaneously due to IL-17A and IL-6 mediated…
Abstract Number: 2793 • 2017 ACR/ARHP Annual Meeting
Joint Location-Specific JAK-STAT Signaling in Rheumatoid Arthritis (RA) Fibroblast-like Synoviocytes (FLS)
Deepa Hammaker¹, Gyrid Nygaard¹, David L. Boyle², Rizi Ai³, Wei Wang⁴ and Gary S. Firestein⁵, ¹Medicine, UC San Diego, La Jolla, CA, ²University of California San Diego, La Jolla, CA, ³UC San Diego, La Jolla, CA, ⁴Chemistry and Biochemistry, UC San Diego, La Jolla, CA, ⁵Medicine, University of California San Diego, La Jolla, CA
Background/Purpose: Aberrant epigenetic marks in RA FLS contribute to disease pathogenesis and aggressive FLS behavior. Computational data also suggest that RA FLS isolated from different…
Abstract Number: 2604 • 2016 ACR/ARHP Annual Meeting
Ultrasound and Immunological Changes and Associations after One Year of IL-6/IL- 6R Blockade with Tocilizumab in Rheumatoid Arthritis Patients
Cesar Diaz-Torne¹, Juan Jose De Agustin², Patricia Moya¹, Maria A. Ortiz³, Delia Reina⁴, Carme Moragues⁵, Sergi Ros⁶, Emili Gomez⁷, Enrique Casado Burgos⁸, Eli Garcia⁹, Manel Pujol¹⁰, Maria Pilar Lisbona Perez¹¹, Andrés Ponce¹², V Torrente¹³, P. Estrada¹⁴, Silvia Vidal³ and ECOCAT group, ¹Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain, ²Rheumatology, Hospital Baix de Llobregat, Barcelona, Spain, ³Institut de Recerca Sant Pau, Barcelona, Spain, ⁴Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, ⁵Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁶Rheumatology, Hospital de Viladecans, Viladecans, Spain, ⁷Rheumatology, Hospital Clínic, Barcelona, Spain, ⁸Hospital Universitari Parc Taulí, Sabadell, Spain, ⁹Rheumatology, Hospital de Mollet, Mollet, Spain, ¹⁰Hospital Mútua de Terrassa, Terrassa, Spain, ¹¹Rheumatology, Hospital de Sabadell, Sabadell, Spain, ¹²Rheumatology. Internal Medicine, Hospital General de Granollers, Granollers, Spain, ¹³Hospital de L'Hospitalet, L'Hospitalet de Llobregat, Spain, ¹⁴Rheumatology, Hospital Moises Broggi, Barcelona, Spain
Background/Purpose: Management of RA patients has improved in the last two decades in part with the use of ultrasound (US) in daily clinical practice. The…
Abstract Number: 60 • 2016 ACR/ARHP Annual Meeting
A Single Nucleotide Polymorphism of IL6-Receptor Is Associated with Response to Tocilizumab in Rheumatoid Arthritis: Results from Toci and ROC Studies
Cécile Luxembourger¹, Adeline Ruyssen-Witrand², Yannick Degboé³, Alain G. Cantagrel¹, Arnaud CONSTANTIN⁴, Philippe Gaudin⁵, Christian Jorgensen⁶, Jean-Francis Maillefert⁷, Hubert Marotte Sr.⁸, Delphine Nigon⁹, Daniel Wendling¹⁰, Jacques-Eric Gottenberg¹¹ and Yves-marie Pers¹², ¹Rheumatology, Centre Hospitalier Universitaire, Toulouse Purpan, Toulouse, France, ²Rheumatology Center, Purpan University Hospital, Toulouse, France, ³Rheumatology, Rheumatology Center, Purpan University Hospital, Toulouse, France, ⁴Rheumatology, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, ⁵Rheumatology, Grenoble University Hospital, France, Grenoble, France, ⁶Inserm u844, Unite ImmunoRhumatologie Therapeutique, Montpellier, France, ⁷Rheumatology, University Hospital, Dijon, France, ⁸CHU de St Etienne, Service de rhumatologie, St Etienne, France, ⁹CHU Purpan, Toulouse, France, ¹⁰Rheumatology, Besançon university hospital, Besançon, France, ¹¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹²coordination RIC SUD, Montpellier, France
Background/Purpose: Biological agents (boDMARDs) have modified the therapeutic management of patients with rheumatoid arthritis (RA). However, boDMARDs can induce sustained remission in only 30% of…
Abstract Number: 1029 • 2016 ACR/ARHP Annual Meeting
Functional Genetics of PTPN2 in Rheumatoid Arthritis: Haploinsufficiency of PTPN2 Promotes Severity of Th17-Cell Mediated Autoimmune Arthritis
Mattias N. D. Svensson^1,2, Karen M. Doody¹, Cristiano Sacchetti^1,2, Dennis J. Wu¹, Gisen Kim³, Annelie Hellvard⁴, Brith Bergum⁴, Piotr Mydel⁴, Mitchell Kronenberg³, Michel L. Tremblay⁵ and Nunzio Bottini^1,2, ¹Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, ²Department of Medicine, University of California, San Diego, La Jolla, CA, ³Developmental Immunology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, ⁴Clinical Science, Broegelmann Research Laboratory, Bergen, Norway, ⁵Goodman Cancer Centre, McGill University, Montréal, QC, Canada
Background/Purpose: Genome-wide association studies have linked polymorphisms in the PTPN2 locus to rheumatoid arthritis (RA). PTPN2 encodes the tyrosine phosphatase TC-PTP, an important regulator of…
Abstract Number: 1581 • 2016 ACR/ARHP Annual Meeting
The Combination of IL-6 and IL-6 Receptor Levels As a Biomarker of Response to Tocilizumab in Rheumatoid Arthritis Patients
Cesar Diaz-Torne¹, Maria A. Ortiz², Patricia Moya³, M. Victoria Hernández⁴, Delia Reina⁵, Ivan Castellvi⁶, Juan Jose De Agustin⁷, Diana De La Fuente⁸, Hector Corominas^9,10, Raimon Sanmarti¹¹, Josep Maria De Llobet Zubiaga¹ and Silvia Vidal², ¹Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain, ²Institut de Recerca Sant Pau, Barcelona, Spain, ³Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁴Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ⁵Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, ⁶Rheumatology, Hospital de Sant Pau, Barcelona, Spain, ⁷Rheumatology, Hospital Baix de Llobregat, Barcelona, Spain, ⁸Rheumatology, Hospital de Viladecans, Barcelona, Spain, ⁹Rheumatology, Hospital Moises Broggi, Barcelona, Spain, ¹⁰Servei de Reumatologia, Hospital Moises Broggi, Barcelona, Spain, ¹¹Arthritis Unit. Rheumatology, Arthritis Unit. Rheumatology Department. Hospital Clínic, Barcelona, Spain
Background/Purpose: Several predictors of response to tocilizumab have been described. They include a low HAQ, high baseline CRP or NK levels and certain IL-6R polymorphisms.…
Abstract Number: 2104 • 2016 ACR/ARHP Annual Meeting
Treatment with Tocilizumab Decreases CXCL13 Expression in Cultured Temporal Arteries from Patients with Giant Cell Arteritis
Nekane Terrades-Garcia¹, Joana Daradoumis², Ester Planas-Rigol², Marc Corbera-Bellalta¹, Sergio Prieto-González², Georgina Espígol-Frigolé² and Maria C. Cid³, ¹Vasculitis Research Unit. Department of Autoimmune Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ²Department of Autoimmune and Systemic Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ³Autoimmune and Systemic Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain
Background/Purpose: IL-6 has been considered a biomarker of disease activity in GCA and a potential therapeutic target. However, the functional role of IL-6 in GCA…
Abstract Number: 2155 • 2016 ACR/ARHP Annual Meeting
Crosstalk Between IL-6 and TNF-Alpha Signaling Pathway in Rheumatoid Arthritis Synovial Fibroblasts
Alvaro Valin¹, Yolanda Ruano², Manuel J. Del Rey³, Carmen M. García-Herrero³, Eduardo Martín-Guerrero¹, Beatriz Bravo⁴, Juan D. Cañete⁵, José L. Rodríguez-Peralto² and Jose L. Pablos^3,6, ¹Grupo de Enfermedades Inflamatorias y Autoimmunes, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain, ²Pathology Department, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain, ³Grupo de Enfermedades Inflamatorias y Autoinmunes, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain, ⁴Servicio de Traumatología y Cirugía Ortopédica, Hospital 12 de Octubre, Madrid, Spain, ⁵Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain, ⁶Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain
Background/Purpose: Although elevated IL-6 and its soluble receptor (sIL6R) have been found in the serum and synovium of arthritic patients, the molecular mechanisms by which…
Abstract Number: 92 • 2015 ACR/ARHP Annual Meeting
Variation at Interleukin-6 Receptor Gene Is Associated to Joint Damage in Rheumatoid Arthritis
María López-Lasanta¹, Antonio Julià¹, Joan Maymo², Benjamin Fernandez Gutierrez³, Inmaculada Ureña⁴, Francisco J. Blanco⁵, Juan D. Cañete⁶, Mercedes Alperi-López⁷, Alejandro Olivé⁸, Hector Corominas⁹, Jesús Tornero¹⁰, Alba Erra¹¹, Miriam Almirall¹², Nuria Palau¹³, Ana M. Ortiz Garcia¹⁴, Gabriela Avila¹³, Luis Rodriguez-Rodriguez¹⁵, Arnald Alonso¹, Raül Tortosa¹, Isidoro González-Alvaro¹⁶ and Sara Marsal¹, ¹Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ²Rheumatology, Hospital del Mar, Barcelona, Spain, ³Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ⁴Rheumatology service, Hospital Regional Universitario Carlos Haya, Malaga, Spain, ⁵Osteoarticular and Aging Research Lab, INIBIC–Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁶Arthritis Unit. Rheumatology, Arthritis Unit. Rheumatology Department. Hospital Clínic, Barcelona, Spain, ⁷Department of Rheumatology, Hospital Universitario Central de Asturias, Asturias, Spain, ⁸Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, ⁹Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, ¹⁰Rheumatology Department, Hospital Universitario Guadalajara, Guadalajara, Spain, ¹¹Rheumatology, Rheumatology Hospital San Rafael, Barcelona, Spain, ¹²Rheumatology Department, Hospital del Mar, Barcelona, Spain, ¹³Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ¹⁴Rheumatology, H.U. La Princesa, Madrid, Spain, ¹⁵Department of Rheumatology, Hospital Clinico San Carlos, Madrid, Spain, ¹⁶Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain
Background/Purpose: Interleukin-6 (IL-6) cytokine signaling is key in Rheumatoid Arthritis (RA) pathophysiology. Blocking IL-6 receptor (IL6R) has proven to be a highly effective treatment to prevent joint…
Abstract Number: 1635 • 2015 ACR/ARHP Annual Meeting
Development of New Bioassay System Measuring Inhibitory Strength of IL-6/STAT3 Signal Under Tocilizumab Treatment in Rheumatoid Arthritis Patients
Shuntaro Saito¹, Katsuya Suzuki¹, Kunihiro Yamaoka¹ and Tsutomu Takeuchi², ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Tocilizumab (TCZ) is a IL-6 receptor blockade, administered intravenously every 4 weeks and efficiently inhibits IL-6/STAT3 signaling pathway. We have previously reported the usefulness…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].